The Filing Desk

Teladoc Health

TDOC · NYSE · Health Care · Financials, fiscal 2016 to 2025

TDOC · Last close · November 13, 2026
$8.80
Value Teladoc Health yourself

Teladoc Health's revenue fell 1.5% to $2.5 billion in fiscal 2025. Its operating margin was −10.4%, up from −39.7% a year earlier. Free cash flow was $285 million, up 0.9%. The diluted share count rose 3.3%.

TELADOC HEALTH, INC. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001477449-26-000012 Updated
Revenue
$2.5B
1.5%
Operating margin
−10.4%
29.3 pts
Net income
−$200M
 
Free cash flow
$285M
0.9%
Return on capital
−12.5%
23.6 pts
Market cap
$1.6B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Teladoc Health does

Teladoc Health provides virtual care: doctor and therapy visits by video, phone, app and text. It sells to employers, health insurers, hospitals and health systems, and also directly to consumers. It says it completed 17.1 million telehealth visits in 2025 across its business and consumer channels.

It reports two segments. Integrated Care sells mostly to employers and insurers, and gives members access to services such as primary care, urgent care, mental health, chronic condition care and expert second opinions. For hospitals and health systems it also sells hardware, software and services for telehealth. BetterHelp is its online counseling and therapy service, which uses a network of nearly 35,000 licensed clinicians.

The company says it uses data, AI and human expertise to guide members to the care they need, and refers them to in-person care when appropriate.

Its biggest risks, as it describes them

  • It has a history of cumulative losses and may never reach lasting profitability.
  • A large part of its revenue comes from a few clients, and losing one could hurt it badly.
  • It may have to write down the value of goodwill and other intangible assets, which would reduce its reported results.
  • The virtual care market may grow more slowly than expected or its services may not draw enough member use.
  • It pays large upfront costs to win clients and may not earn them back if clients leave.
From Teladoc Health's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Teladoc Health lost money in fiscal 2025: a net loss of $200 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments8969181,1241,298781
Debt incl. finance leases1,2261,5351,5391,542995
Net debt (negative means net cash)330617415244214
Net debt to EBITDA——4.7x—2.1x
Debt to equity0.1x0.7x0.7x1.0x0.7x
Interest coverage−3.3x−622.2x−11.2x−42.9x−13.3x
Current ratio3.7x3.3x3.5x1.8x2.8x
Quick ratio3.5x3.1x3.5x1.7x2.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Teladoc Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $69,400 of Teladoc Health shares on the open market, and 6 insiders sold $2.4 million, $493,821 of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 11, 2026Charles Divita IIIChief Executive Officer, DirectorSold17,805$6.10$108,610Form 4
Sep 3, 2026Fernando M. RodriguesPresident of BetterHelpSold plan9,812$6.51$63,876Form 4
Sep 2, 2026Charles Divita IIIChief Executive Officer, DirectorSold18,327$6.30$115,460Form 4
Sep 2, 2026Adam C VandervoortChief Legal Officer, SecretarySold7,573$6.30$47,710Form 4
Sep 2, 2026Kelly BlissPresident, U.S. Group HealthSold7,357$6.30$46,349Form 4
Sep 2, 2026Carlos NuenoPresident, InternationalSold6,200$6.30$39,060Form 4
Sep 2, 2026Fernando M. RodriguesPresident of BetterHelpSold plan5,439$6.30$34,266Form 4
Sep 2, 2026Joseph Ronald CatapanoChief Accounting OfficerSold274$6.30$1,726Form 4
Jul 6, 2026Kelly BlissPresident, U.S. Group HealthSold plan2,500$9.50$23,750Form 4
Jul 2, 2026Joseph Ronald CatapanoChief Accounting OfficerSold653$9.10$5,942Form 4
Jul 1, 2026Kelly BlissPresident, U.S. Group HealthSold plan2,500$9.00$22,500Form 4
Jun 29, 2026Kelly BlissPresident, U.S. Group HealthSold plan2,500$8.50$21,250Form 4
The latest 12 of 37 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score5 of 82 of 86 of 8
Rule of 4021.1%9.8%9.7%
Altman Z''−8.91−14.88−16.73
Accruals ratio−13.1%−32.8%−15.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positivePassPassPass
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailPass
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailPass
F-score5 of 82 of 86 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Teladoc Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Teladoc HealthFY25−1.5%−10.4%11.3%−12.5%2.1x6
ChemedFY254.1%13.4%12.9%27.3%−0.2x5Compare
Aveanna HealthcareFY2520.2%10.5%—21.6%4.1x7Compare
Hims & Hers HealthFY2559.0%4.5%2.5%19.0%2.5x4Compare
Amn Healthcare ServicesFY25−8.5%−2.0%8.6%−2.8%7.2x5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue1232334185531,0942,0332,4072,6022,5702,530
Revenue growth59.1%89.4%79.1%32.4%97.7%85.8%18.4%8.1%−1.3%−1.5%
Gross profit911722893697031,3821,663———
Research and development22345465165312334348307278
Operating income−63−75−71−80−506−266−13,653−249−1,021−263
Net income−74−107−97−99−485−429−13,660−220−1,001−200
Diluted EPS (US$)−1.75−1.93−1.47−1.38−5.36−2.73−84.60−1.34−5.87−1.14
Diluted shares (millions)4255667290157162165171176
Cash flow
Cash from operations−52−34−530−54194189350294294
Capital expenditure2344481612119
Free cash flow−54−37−926−58185173339283285
Dividends paid0000000000
Share buybacks0000000000
Acquisitions37379282115677900082
Stock-based compensation831446747630321820214680
Balance sheet at fiscal year end
Cash and short-term investments50434785177878969181,1241,298781
Debt incl. finance leases442074154401,4221,2261,5351,5391,542995
Total assets3048241,5291,60317,75517,7354,3454,3923,5162,858
Total liabilities732665165891,8721,6892,0382,0662,0251,473
Shareholders' equity2315591,0131,01415,88416,0462,3082,3261,4911,386
Margins and ratios
Gross margin74.0%73.6%69.2%66.7%64.3%68.0%69.1%———
Operating margin−50.9%−32.3%−16.9%−14.5%−46.3%−13.1%−567.3%−9.6%−39.7%−10.4%
Net margin−60.3%−45.8%−23.2%−17.9%−44.4%−21.1%−567.5%−8.5%−39.0%−7.9%
Free cash flow margin−43.8%−15.9%−2.1%4.8%−5.3%9.1%7.2%13.0%11.0%11.3%
Rule of 40 (growth + FCF margin)15.3%73.5%77.0%37.2%92.5%94.9%25.6%21.1%9.8%9.7%
Return on capital−26.4%−12.6%−6.7%−6.7%−4.6%−1.3%−111.8%−6.9%−36.0%−12.5%
Return on equity−36.2%−27.0%−12.3%−9.8%−5.7%−2.7%−148.8%−9.5%−52.5%−13.9%
Return on assets−27.8%−18.9%−8.2%−6.3%−5.0%−2.4%−123.7%−5.0%−25.3%−6.3%
Net debt to EBITDA———————4.7x—2.1x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Teladoc Health's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Teladoc Health.